Gray­bug seeks al­ter­na­tive op­tions for eye drugs; RA-backed epilep­sy out­fit se­cures $40M Se­ries C

Gray­bug Vi­sion is in search of a new home about 21 months af­ter land­ing on the Nas­daq. The oc­u­lar dis­ease-fo­cused biotech has seen its stock $GRAY plum­met amid the biotech bear mar­ket, nose­div­ing from a Sep­tem­ber 2020 list­ing at $16 to $1 ter­ri­to­ry the past few months.

The Bal­ti­more com­pa­ny’s stock is re­bound­ing Tues­day morn­ing, though, thanks to an an­nounce­ment be­fore the open­ing bell that the gene ther­a­py de­vel­op­er would seek a strate­gic al­ter­na­tive thanks to the help of fi­nan­cial ad­vi­sor Piper San­dler.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.